Status:
COMPLETED
Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches
Lead Sponsor:
Assiut University
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The RA patients receiving leflunomide for more than one month, and not receiving other DMARDs (except hydroxychloroquine), will be enrolled to assess their disease activity. Blood samples will be coll...
Eligibility Criteria
Inclusion
- Rheumatoid arthritis patients already receiving leflunomide with or without Hydroxychloroquine but without other Disease modifying agents
Exclusion
- Those diagnosed with other rheumatic diseases or Rheumatoid patients receiving disease modifying agents other than leflunomide
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04022525
Start Date
February 1 2018
End Date
December 31 2019
Last Update
September 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Hospital
Asyut, Egypt